• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients

byConstance Wu
October 13, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Sodium phenylbutyrate-taurursodiol slowed the functional decline in patients with amyotrophic lateral sclerosis.

2. The mean rate of change for slow vital capacity and plasma phosphorylated axonal neurofilament H subunit were not significantly different between the treatment and control groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Amyotrophic lateral sclerosis (ALS) causes motor neuron degeneration in the motor cortex of the spinal cord which leads to progressive muscle weakness. Current approved treatments manage symptoms, however, they do not slow neuronal degeneration. The coformulation of sodium phenylbutyrate and taurursodiol reduce neuronal death, ease endoplasmic reticulum stress, and mitigate mitochondrial function. As such, this study evaluated the safety and efficacy of sodium phenylbutyrate-taurursodiol in patients with ALS. The results of this study demonstrated that coformulation slowed the functional decline in patients though causing more adverse events. This randomized trial had several limitations including the quantification strategy. Further, the study used the Revised Amyotrophic Lateral Sclerosis Functional Ration Scale (ALSFRS-R), which has been suggested to not be a valid representation of disease severity. Nonetheless, the results of this study are significant as it evaluated a new therapy for a disorder with very few treatment possibilities.

Click to read the study in NEJM

Relevant Reading: Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model

In-Depth [randomized controlled trial]: This randomized control trial enrolled 137 participants in a multicenter study at 25 centers in the United States. Participants included in the study had a definite ALS diagnosis and had a slow vital capacity (SVC) of at least 60%. Participants with symptom onset longer than 18 months were excluded from this study. Study participants were randomized in a 2:1 ratio to receive sodium phenylbutyrate-taurursodiol or placebo, respectively. The primary outcome was the rate slope of decline in the total score on the ALSFRS-R from baseline. The ALSFRS-R contains 12 items across four subdomains of bodily function such as bulbar, fine motor, gross motor, and breathing. The total scale ranges from 0 to 48 with a higher score indicating better function. At week 24, the estimated mean rate of change in the ALSFRS-R total score was -1.24 points per month with the active-drug group compared to -1.66 points per month with placebo (difference, 0.42 points per month; 95% confidence interval [CI], 0.03 to 0.81; P=0.03). Additionally, secondary outcomes were also analyzed during the study. The mean rate of change in the plasma phosphorylated axonal neurofilament H subunit (pNF-H) concentration was 3.58 picogram (pg) per milliliter per month with the active-drug treatment compared to -2.34 pg per milliliter per month with placebo treatment (difference, 5.92 pg per milliliter per month, 95% CI, -4.41 to 16.26). The mean rate of change in SVC was -3.10% of the predicted normal value per month in the sodium phenylbutyrate-taurursodial group compared to -4.03% of the predicted normal value per month in the placebo group (difference, 0.93 percentage points per month; 95% CI, -0.10 to 1.95). Also, the cumulative hazard ratio for death, tracheostomy, or hospitalization in the active-drug group compared to placebo was 0.53 (95% CI, 0.27 to 1.05). Taken together, the sodium phenylbutyrate-taurursodiol coformulation slowed the functional decline of patients with ALS.

RELATED REPORTS

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

Intravenous tenecteplase non-inferior to alteplase for patients with acute ischemic strokes

Difelikefalin reduces pruritus in adults with notalgia paresthetica

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ALSamyotrophic lateral sclerosisamyotrophic lateral sclerosis (ALS)neurologysodium phenylbutyrate-taurursodialsodium phenylbutyrate-taurursodiol
Previous Post

Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer

Next Post

#VisualAbstract: Active malignancy during COVID-19 infection not associated with increased risk of ICU admission, intubation, or death

RelatedReports

Proton radiotherapy may be effective for refractory pituitary adenomas
Chronic Disease

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

March 18, 2023
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Intravenous tenecteplase non-inferior to alteplase for patients with acute ischemic strokes

March 7, 2023
Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Chronic Disease

Difelikefalin reduces pruritus in adults with notalgia paresthetica

February 16, 2023
Early palliative care may improve survival in advanced cancer
Neurology

Spirituality has mixed effects on outcomes in ALS patients and caregivers

February 10, 2023
Next Post
#VisualAbstract: Early physical therapy effective in reducing disability for patients with lower back pain

#VisualAbstract: Active malignancy during COVID-19 infection not associated with increased risk of ICU admission, intubation, or death

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Midwifery continuity of care model not associated with improved clinical outcomes compared to standard care

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options